Long-Term Survival After LVAD Implantation in End-Stage Heart Failure

NCT07382284 · tracked via the Priya Life Science China tracker

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase

Observational

Started

2022-07-17

Last updated

2026-02-02

Condition(s) studied

End-stage Heart Failure

Investigational drug(s) / intervention(s)

Left Ventricular Assist Device (LVAD) implantation

Left Ventricular Assist Device (LVAD) implantation: Left ventricular assist device (LVAD) implantation performed as part of routine clinical care for patients with end-stage heart failure. This study is observational in nature and does not assign, alter, or mandate any intervention. The decision to implant an LVAD, the type of device used, perioperative management, and postoperative treatment are determined solely by the treating clinical team according to standard clinical practice.

Study summary

This is a prospective, observational, multi-center cohort study designed to evaluate long-term survival and clinical outcomes in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation.

Patients receiving LVAD implantation as part of routine clinical care will be enrolled and followed for up to 3-5 years. During the study period, data will be collected on baseline characteristics, preoperative medical therapy, intraoperative surgical information, in-hospital course, and long-term postoperative medication use, as well as survival status, major clinical outcomes, LVAD-related complications, and hospital readmissions.

In addition, myocardial tissue samples will be obtained from the left ventricular apex during LVAD implantation surgery. These tissue samples are routinely removed as part of the standard surgical procedure and would otherwise be discarded after pathological examination. Peripheral blood samples will also be collected at predefined time points as part of routine clinical blood testing. No additional surgical procedures or invasive interventions are required for this study.

This study does not involve any experimental treatment or changes to standard medical care. All treatments and follow-up assessments are determined by the treating physicians according to routine clinical practice.

The purpose of this study is to improve understanding of long-term outcomes after LVAD implantation and to explore potential biological factors associated with prognosis in patients with end-stage heart failure.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Adults aged ≥18 years 2. Diagnosis of end-stage heart failure refractory to optimal medical therapy 3. Scheduled to undergo left ventricular assist device (LVAD) implantation as part of routine clinical care 4. Able to provide written informed consent for participation and biospecimen collection 5. Willing and able to comply with study procedures and long-term follow-up 6. Availability of left ventricular apical myocardial tissue obtained during LVAD implantation surgery 7. Availability of peripheral blood samples collected during routine clinical care 8. Patients treated at participating study centers Exclusion Criteria: 1. Age \<18 years 2. Prior implantation of a durable mechanical circulatory support device 3. Concomitant heart transplantation at the time of index surgery 4. Congenital heart disease requiring complex surgical repair 5. Active systemic infection or sepsis at the time of LVAD implantation 6. Known active malignancy with a life expectancy \<1 year 7. Severe non-cardiac comorbidities limiting expected survival to less than 1 year (e.g., advanced liver failure, end-stage renal disease not eligible for renal replacement therapy) 8. Inability or unwillingness to provide informed consent 9. Pregnancy or breastfeeding at the time of enrollment 10. Inadequate quantity or quality of myocardial tissue or peripheral blood samples for planned analyses

Primary outcome measure(s)

Clinical response after LVAD implantation — During longitudinal follow-up up to 5 years after LVAD implantation
Patients will be classified as responders or non-responders based on predefined criteria.

Trial sites (1)

Facility	City	Region	Status
+86 025 83106666	Nanjing	Jiangsu	Recruiting

More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China

Food Intake-Related Brain and Metabolic Responses in Obesity Recruiting

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer Recruiting

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors Recruiting

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Recruiting

Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy Recruiting

Other trials for the same condition

Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07382284 on ClinicalTrials.gov ↗ ← All trials in China